<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02909114</url>
  </required_header>
  <id_info>
    <org_study_id>CH-GI-096</org_study_id>
    <nct_id>NCT02909114</nct_id>
  </id_info>
  <brief_title>Stereotactic Body Radiotherapy for Oligometastases From Colorectal Cancer</brief_title>
  <official_title>Phase II Study of Stereotactic Body Radiotherapy for Oligometastases From Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jing Jin, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single arms prospective phase II study of SBRT for oligometastatases from colorectal cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single arms prospective phase II study of SBRT for oligometastatases from colorectal cancer,
      the primary concerns are treatment efficacy and toxicities.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>local control assessed by RECIST</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>&gt;= Grade 3 treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>from radiotherapy start to complete treatment 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SBRT for oligometastatases from colorectal cancer objectives</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic body radiotherapy</intervention_name>
    <description>All patients will undergo planning CT simulation. 4-dimensional CT will be used for tumors in the lungs or liver. For all lesions, the gross tumor volume (GTV) will be defined as the visible tumor on CT and/or MRI imaging +/- PET. A Planning Target Volume (PTV) margin of 3-5 mm will be added depending on site of disease, immobilization, and institutional set-up accuracy.
The prescirbe dosage was as following: Lung lesion DT50-60 Gy/5 fractions; liver 50-60Gy/5-8 fractions; brain DT 40Gy/4-5fractions. All will be treated with SBRT</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-75 years

          -  Eastern Cooperative Oncology Group (ECOG) performance score ≤ 1

          -  Diagnosis by pathological examination

          -  Primary lesion is under control by surgery

          -  Adequate blood counts:

               -  White blood cell count ≥3.5 x 109/L

               -  Haemoglobin levels ≥100g/L

               -  Platelet count ≥100 x 109/L

               -  Creatinine levels ≤1.0× upper normal limit (UNL)

               -  Urea nitrogen levels ≤1.0× upper normal limit (UNL)

               -  Alanine aminotransferase (ALT) ≤1.5× upper normal limit (UNL)

               -  Aspartate aminotransferase (AST) ≤1.5× upper normal limit (UNL)

               -  Alkaline phosphatase (ALP) ≤1.5× upper normal limit (UNL)

               -  Total bilirubin (TBIL) ≤1.5× upper normal limit (UNL)

        Exclusion Criteria:

          -  Primary lesion is not under control

          -  Pancreatic carcinoma

          -  Oligometastases could not be located

          -  Pregnancy or breast feeding

          -  Symptoms or history of peripheral neuropathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ning Li, Doctor</last_name>
    <phone>13810381399</phone>
    <phone_ext>+86</phone_ext>
    <email>lee_ak@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jing Jin, Doctor</last_name>
    <phone>13601365130</phone>
    <phone_ext>+86</phone_ext>
    <email>jingjin1025@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Acadamy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>10021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ning Li, Doctor</last_name>
      <phone>13810381399</phone>
      <phone_ext>0086</phone_ext>
      <email>lee_ak@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Jing Jin</last_name>
      <phone>13601365130</phone>
      <phone_ext>0086</phone_ext>
      <email>jingjin1025@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2016</study_first_submitted>
  <study_first_submitted_qc>September 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2016</study_first_posted>
  <last_update_submitted>September 20, 2016</last_update_submitted>
  <last_update_submitted_qc>September 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Jing Jin, M.D.</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>stereotactic boday radiotherapy, oligometastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

